Randomized Trialhigh evidence
Dapagliflozin for Renal Protection in Heart Transplant Recipients: A Randomized Clinical Trial.
Circulation·November 8, 2026·PMID 42999953
Why it mattersProgressive kidney disease in heart transplant recipients is driven by calcineurin inhibitor exposure and comorbidities, yet SGLT2 inhibitor evidence in this population is sparse. This trial provides randomized data that dapagliflozin may slow eGFR decline, addressing a key unmet need in post-transplant cardiorenal protection.

The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled